Global private equity and venture capital news and research

Posts Tagged ‘Novartis Venture Funds’

29 January 2015

Atlas Genetics raises $20m Series C to make infectious disease testing easier

take-a-blood-sample-1428179-m Atlas Genetics, a developer of diagnostic testing for infectious diseases, has closed a $20m Series C financing round from an investor group including new investor RMI Partners.

17 December 2014

Novartis Venture leads $34m round for Annexon Bioscience

test-tubes-1-1416029-m Novartis Venture Funds has led a $34m Series A-1 funding round for neurodegenerative treatment company Annexon Bioscience.

24 October 2014

Atlas leads $17m round in Quartet Medicine

biotech lab clinic research Venture capital firm Atlas Venture has led a $17m Series A financing in bio-tech company Quartet Medicine.

19 May 2014

Sorbent Therapeutics secures $6.5m

medical monitor Biopharmaceutical startup Sorbent Therapeutics, which is focused on developing therapies for cardiovascular and renal diseases, has closed a $6.5m tranche in its $15m Series D funding round.

30 April 2014

Infectious disease tester Atlas picks up £16.9m venture capital backing

virus2_sq UK-based infectious disease testing company Atlas Genetics has raised £16.9m in Series B funding from a string of venture capital firms.

23 April 2014

OrbiMed leads $22m round for Aerpio Therapeutics

biotech_lrg Biopharmaceutical startup Aerpio Therapeutics has secured $22m in a round led by venture capital firm OrbiMed.

15 May 2013

Apple Tree and Novartis back Tokai’s $35m Series E

pharmaceutical 12_sq Cancer-focused biotech firm Tokai Pharmaceuticals has wrapped up a $35m Series E round, which was supported by existing investors Apple Tree Partners and Novartis Venture Funds.

31 October 2012

Novo, Novartis lead $16m Series A for Thesan Pharmaceuticals

Thesan Pharmaceuticals has closed a $16m Series A round, co-led by corporate investment group Novo Ventures and life sciences-focused Novartis Venture Funds.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2015